NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
11.68
+0.05 (0.43%)
At close: Dec 18, 2025, 4:00 PM EST
11.63
-0.05 (-0.43%)
After-hours: Dec 18, 2025, 5:13 PM EST
NeoGenomics Revenue
NeoGenomics had revenue of $187.80M in the quarter ending September 30, 2025, with 11.90% growth. This brings the company's revenue in the last twelve months to $709.16M, up 10.10% year-over-year. In the year 2024, NeoGenomics had annual revenue of $660.57M with 11.65% growth.
Revenue (ttm)
$709.16M
Revenue Growth
+10.10%
P/S Ratio
2.09
Revenue / Employee
$322,346
Employees
2,200
Market Cap
1.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 660.57M | 68.92M | 11.65% |
| Dec 31, 2023 | 591.64M | 81.92M | 16.07% |
| Dec 31, 2022 | 509.73M | 25.40M | 5.24% |
| Dec 31, 2021 | 484.33M | 39.88M | 8.97% |
| Dec 31, 2020 | 444.45M | 35.62M | 8.71% |
| Dec 31, 2019 | 408.83M | 132.09M | 47.73% |
| Dec 31, 2018 | 276.74M | 36.49M | 15.19% |
| Dec 31, 2017 | 240.25M | 8.44M | 3.64% |
| Dec 31, 2016 | 231.81M | 132.01M | 132.27% |
| Dec 31, 2015 | 99.80M | 12.73M | 14.62% |
| Dec 31, 2014 | 87.07M | 20.60M | 31.00% |
| Dec 31, 2013 | 66.47M | 6.60M | 11.02% |
| Dec 31, 2012 | 59.87M | 16.38M | 37.68% |
| Dec 31, 2011 | 43.48M | 9.11M | 26.51% |
| Dec 31, 2010 | 34.37M | 4.90M | 16.63% |
| Dec 31, 2009 | 29.47M | 9.45M | 47.23% |
| Dec 31, 2008 | 20.02M | 8.51M | 73.97% |
| Dec 31, 2007 | 11.50M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NEO News
- 3 days ago - NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Business Wire
- 8 days ago - NeoGenomics to Present New ctDNA Research at SABCS 2025 - Business Wire
- 10 days ago - NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 - Business Wire
- 4 weeks ago - Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - NeoGenomics to Participate in Upcoming Investor Conferences - Business Wire
- 7 weeks ago - NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors - Business Wire
- 7 weeks ago - NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - NeoGenomics Reports Third Quarter 2025 Results - Business Wire